Next-Generation Non-Hodgkin Lymphoma Care: Spotlight on Therapeutic Approaches Targeting Protein Degradation Pathways

Learn more about cereblon E3 ligase modulators (CELMoDs) in the treatment of patients with non-Hodgkin lymphoma through a downloadable resource, on-demand webcast, and podcast including the latest available data.

Share

Program Content

Activities

CELMoDs in NHL
Practical Considerations for CELMoDs in NHL
PDF
Congratulations: You achieved a completion on 04/09/2022

Released: May 23, 2024

Expires: May 22, 2025

Faculty

cover img faculity

Julio C. Chavez, MD, MS

Associate Member
Department of Malignant Hematology
ICE-T Clinical Research Medical Director for Hematologic Malignancies
H. Lee Moffitt Cancer Center and Research Institute
Associate Professor
University of South Florida
Tampa, Florida

cover img faculity

Alan Skarbnik, MD

Director, Lymphoma and CLL Program
Director, Immune Effector Cell Therapeutics Program
Novant Health Cancer Institute
Charlotte, North Carolina

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC

Supporters

Supported by an educational grant from Bristol Myers Squibb.

Bristol Myers Squibb